An interventional study of ACUVUE OASYS 1-Day for Astigmatism (AO1DfA) and Dailies Total 1 for Astigmatism (DT1fA) in Visual Acuity, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Johnson & Johnson Vision Care, Inc. · Not applicable, Interventional, and Treatment
This will be a single site, 2-visit, randomized, controlled, single-masked, non-dispensing, bilateral wear, 2x2 cross over study to assess visual acuity.
Johnson & Johnson Vision Care, Inc. is the lead sponsor of 220 studies on the registry; 2 are open to participants now.
Of its 110 completed or terminated interventional studies of FDA-regulated products, 101 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Eligible subjects will be randomized into the AO1DfA/DT1fA wear sequence, to wear the test lens followed by the control lens, bilaterally, with a 1-to-10 day(s) washout period between wear periods.
Device: ACUVUE OASYS 1-Day for Astigmatism (AO1DfA) · Device: Dailies Total 1 for Astigmatism (DT1fA)
Eligible subjects will be randomized into the DT1Fa/AO1DfA wear sequence, to wear the control lens followed by the test lens, bilaterally, with a 1-to-10 day(s) washout period between wear periods.
Device: ACUVUE OASYS 1-Day for Astigmatism (AO1DfA) · Device: Dailies Total 1 for Astigmatism (DT1fA)
Test Lens
Control Lens
Distance Monocular Visual Acuity (LogMAR)
Distance visual acuity was measured monocularly at 6 meters after lens fitting under high-luminance high contrast (HLHC) lighting conditions using the Eurolens computerized logMAR VA chart. Lower scores indicate better visual acuity. A value of 0.0 logMAR is equivalent to 20/20 vision on a Snellen visual acuity chart.
Time frame: Approximately 15-minutes Post Lens Insertion
A total of 6 subjects were enrolled at a single clinical site. Of those enrolled, 1 subject failed to meet all eligibility criteria and 5 subjects were dispensed both study lenses and completed the study.
| Milestone | Delefilcon A/Senofilcon A | Senofilcon A/Delefilcon A |
|---|---|---|
| Started | 2 | 3 |
| Completed | 2 | 3 |
| Not completed | 0 | 0 |
| Milestone | Delefilcon A/Senofilcon A | Senofilcon A/Delefilcon A |
|---|---|---|
| Started | 2 | 3 |
| Completed | 2 | 3 |
| Not completed | 0 | 0 |
Distance visual acuity was measured monocularly at 6 meters after lens fitting under high-luminance high contrast (HLHC) lighting conditions using the Eurolens computerized logMAR VA chart. Lower scores indicate better visual acuity. A value of 0.0 logMAR is equivalent to 20/20 vision on a Snellen visual acuity chart.
| logMAR | Senofilcon A | Delefilcon A |
|---|---|---|
| Distance Monocular Visual Acuity (LogMAR) | -0.07 ± 0.084 | -0.07 ± 0.050 |
Collected over Throughout the duration of the study; approximately 1-10 days per subject.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Senofilcon A | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Delefilcon A | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
All subjects dispensed a study lens.
| Age, Continuous(Years) | All Dispensed Subjects |
|---|---|
| Mean | 32.6 ± 5.94 |
| Sex: Female, Male(Participants) | All Dispensed Subjects |
|---|---|
| Female | 2 |
| Male | 3 |
| Race (NIH/OMB)(Participants) | All Dispensed Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Dispensed Subjects |
|---|---|
| United Kingdom | 5 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johnson & Johnson Vision Care, Inc.